Tissue factor pathway inhibitor binds to platelet thrombospondin-1.
Tissue factor pathway inhibitor (TFPI) is a Kunitz-type serine proteinase inhibitor that down-regulates tissue factor-initiated blood coagulation. The most biologically active pool of TFPI is associated with the vascular endothelium, however, the biochemical mechanisms responsible for its cellular binding are not entirely defined. Proposed cellular binding sites for TFPI include nonspecific association with cell surface glycosaminoglycans and binding to glycosyl phosphatidylinositol-anchored proteins. Here, we report that TFPI binds specifically and saturably to thrombospondin-1 (TSP-1) purified from platelet alpha-granules with an apparent K(D) of approximately 7.5 nm. Binding is inhibited by polyclonal antibodies against TFPI and partially inhibited by the B-7 monoclonal anti-TSP-1 antibody. TFPI bound to immobilized TSP-1 remains an active proteinase inhibitor. Additionally, in solution phase assays measuring TFPI inhibition of factor VIIa/tissue factor catalytic activity, the rate of factor Xa generation was decreased 55% in the presence of TSP-1 compared with TFPI alone. Binding experiments done in the presence of heparin and with altered forms of TFPI suggest that the basic C-terminal region of TFPI is required for TSP-1 binding. The data provide a mechanism for the recruitment and localization of TFPI to extravascular surfaces within a bleeding wound, where it can efficiently down-regulate the procoagulant activity of tissue factor and allow subsequent aspects of platelet-mediated healing to proceed.
Mast
A E
AE
Research and Pathology Services, Department of Veterans Affairs, Departments of Pathology and Anatomy, University of Tennessee, Memphis, Tennessee 38104, USA. alan@pathology.utmem.edu
Stadanlick
J E
JE
Lockett
J M
JM
Dietzen
D J
DJ
Hasty
K A
KA
Hall
C L
CL
D000906:Antibodies / Q000494:pharmacology; D001665:Binding Sites; D001777:Blood Coagulation / Q000502:physiology; D001792:Blood Platelets / Q000737:chemistry / Q000166:cytology; D002384:Catalysis; D003594:Cytoplasmic Granules / Q000737:chemistry; D015536:Down-Regulation; D015942:Factor VIIa / Q000037:antagonists & inhibitors / Q000378:metabolism; D015951:Factor Xa / Q000378:metabolism; D065427:Factor Xa Inhibitors; D006493:Heparin / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D008074:Lipoproteins / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D009154:Mutation; D011485:Protein Binding / Q000187:drug effects; D017434:Protein Structure, Tertiary; D011994:Recombinant Proteins / Q000235:genetics / Q000378:metabolism; D015842:Serine Proteinase Inhibitors / Q000737:chemistry / Q000235:genetics / Q000276:immunology / Q000378:metabolism*; D013379:Substrate Specificity; D019700:Thrombospondin 1 / Q000276:immunology / Q000378:metabolism*
D000906:Antibodies; D065427:Factor Xa Inhibitors; D008074:Lipoproteins; D011994:Recombinant Proteins; D015842:Serine Proteinase Inhibitors; D019700:Thrombospondin 1; C051928:lipoprotein-associated coagulation inhibitor; D006493:Heparin; D015942:Factor VIIa; D015951:Factor Xa